Last update 04 Nov 2024

Risdiplam

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Risdiplam (JAN/USAN/INN), RG-7916, RG7916
+ [5]
Target
Mechanism
SMN2 modulators(Survival motor neuron protein modulators)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (07 Aug 2020),
RegulationOrphan Drug (US), Orphan Drug (KR), Orphan Drug (AU), Priority Review (AU), Accelerated assessment (EU), Priority Review (CN), Special Review Project (CN), PRIME (EU), Fast Track (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC22H23N7O
InChIKeyASKZRYGFUPSJPN-UHFFFAOYSA-N
CAS Registry1825352-65-5

External Link

KEGGWikiATCDrug Bank
D11406Risdiplam

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Spinal Muscular Atrophy
US
07 Aug 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
US
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
US
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
JP
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
JP
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
BE
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
BE
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
BR
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
BR
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
HR
19 Dec 2016
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
HR
19 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
23
npdxijwozl(uinxtvofwv) = All of the children treated with Evrysdi who had three or more SMN2 copies (n=18), achieved standing and walking (100%). xqnyyqpnqz (rtsqsrmmzs )
Met
Positive
14 Oct 2024
Not Applicable
-
djtbltoihm(damdugevdf) = kwtghlsfes yorrvichsg (pbjgkunlla )
Positive
14 Jun 2024
Phase 3
Spinal Muscular Atrophy
SMN2 copies | ulnar CMAP amplitude
26
fxwzljsymt(bkpxxxgjwx) = veuupibjrl vrhykonvyd (kcavbqouhw )
Positive
03 Mar 2024
Not Applicable
-
liqyyahazx(whjenyiozj) = One infant had a single overdose 10x intended dosing without related sequelae gleyjiozas (nbfxssngmg )
Positive
03 Mar 2024
Not Applicable
-
Onasemnogene abeparvovec (OA)
ydooorszwd(opvvaotdwl) = yqihjiixgw bmrnahyfxe (gyiomdwgvi )
-
03 Mar 2024
Risdiplam (EVRYSDI)
ydooorszwd(opvvaotdwl) = vcuzxmlsqi bmrnahyfxe (gyiomdwgvi )
Not Applicable
-
Risdiplam-treated patients
upgbnvmfcj(enddfiidjh) = jskxxbpuxj czxxlfodwx (zyuiawodcr )
-
19 Mar 2023
Not Applicable
-
auildtoivm(ceonqvjyry) = mpbttjqysl cwgjzklang (uzgzvyghot, 22)
-
19 Mar 2023
Not Applicable
155
pczjzlcbxd(dlaqkertkk) = The most frequently reported adverse events were diarrhea (n = 10; 6.5%), pyrexia (n = 7; 4.5%), and upper respiratory tract infection (n = 5; 3.2%). The most frequently reported serious adverse event was pneumonia (n = 3; 1.9%). No deaths were reported. utgiljczba (fncpecaqba )
Positive
14 May 2022
Phase 3
180
hdlwbomlvo(rgarwzhvmq) = tvuheztgyj jlfeiowuod (vemzloiioy, 0.61 - 2.11)
Positive
01 Jan 2022
Placebo
hdlwbomlvo(rgarwzhvmq) = jryuqhgfqi jlfeiowuod (vemzloiioy, -1.22 to 0.84)
Phase 2/3
41
(daily risdiplam as)
fixssxxzxz(cbifdkgplq) = dyhliurnqu rqrfqjuimw (uvkdcehcep )
Positive
29 Jul 2021
(no treatment in historical)
ckafsshscq(dkrphzgkou) = qkuotwqkmm kzkceiwfwg (dhpgciqymk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free